Skip to content
Medical Health Aged Care, Research Development

Renowned specialist breast surgeon to collaborate with research group.

bella PR, on behalf of: Dr Nicole Yap and Fiona Elsey Cancer Research Institute 3 mins read

The Fiona Elsey Cancer Research Institute has announced that renowned Melbourne specialist breast surgeon, Dr Nicole Yap, will work with the Breast cancer research group as a Collaborating Clinician in metropolitan Melbourne. Through this collaboration, Dr Yap will bring her patients perspective to the work and highlight the groups research of to a wider audience.

 

Dr Nicole Yap is a Specialist Breast Surgeon and founding director of Australian Breast Care Centre (ABCC). Dr Yap treats both the cancer and the cosmetic outcome at the same oncoplastic surgery, maintaining or possibly improving the aesthetic/cosmetic outcome. Dr Yap is involved with multiple associations including deputy chair of RACS, AMA councillor, President Chinese Medical Association of Victoria, Vice President of Medical Legal Society Victoria and sits on the board of Pink Hope.

 

Breast cancer is one of the most common cancers in women with one million cases of breast cancer diagnosed around the world each year. Triple-negative breast cancers account for 10%–20% of breast cancers and have been reported to be more aggressive and associated with poorer survival than other subtypes of breast cancers. Notably, the triple-negative subtype of breast cancer is encountered more often in pregnancy and has an aggressive clinical course.

 

The breast cancer researchers at the Fiona Elsey Cancer Research Institute are focused on this aggressive subtype of breast cancer. 

 

In world first work, the group have reported the behaviour and function of a pregnancy associated plasma protein (PAPPA), that is highly found in aggressive triple-negative breast cancers. High PAPPA concentrations are generally detected in blood of pregnant women. However, in breast cancer patients, researchers found that an abnormal overexpression of PAPPA negatively affects survival rates and increases the risk of the cancer recurring. The research sought to understand its functional consequences, and findings revealed that PAPPA plays an important role in regulating key cell motility networks in breast cancers.

 

“As the first Metropolitan based breast surgeon to be accepted as a collaborating clinician, I am honoured to officially support this important research and I encourage other breast cancer surgeons to follow in my footsteps to help bring more patient perspectives and expose the research to a wider audience.” Dr Nicole Yap

 

“I have chosen to donate my resources to the FECRI based on their current studies which align with my charity Australian Breast Care Centre. Triple negative breast cancer is one of the most aggressive breast cancers and tends to be associated with women under the age of 50 and certain genetic mutations.” Said Dr Yap.

 

“We are fortunate to have Dr Yap support of our Breast cancer group. We are grateful for her interest in our work here in Ballarat and look forward to working with her. ”Professor George Kannourakis, Director of the Fiona Elsey Cancer Research Institute

 


Key Facts:

Breast cancer is one of the most common cancers in women with one million cases of breast cancer diagnosed around the world each year. Triple-negative breast cancers account for 10%–20% of breast cancers and have been reported to be more aggressive and associated with poorer survival than other subtypes of breast cancers. Notably, the triple-negative subtype of breast cancer is encountered more often in pregnancy and has an aggressive clinical course.


About us:

For more information on the Fiona Elsey Cancer Reserarch Institute, please visit https://fecri.org.au/

For more information about Dr Nicole Yap, please visit https://www.drnicoleyap.com.au/ or https://www.australianbreastcarecentre.com.au/

 

 


Contact details:

For all media enquiries for Dr Nicole Yap, please contact: bella PRBelinda Visser mb. 0431 27 41 69 e. belinda@bellapr.com.au 

For all media enquiries for Professor George Kannourakis, please contact: Fiona Elsey Cancer Research Institute, Sarah Stapleton mb. 0475 383 687 e. sarah@fecri.org.au

 

Media

More from this category

  • Medical Health Aged Care, Research Development
  • 06/09/2024
  • 15:19
La Trobe University

Breakthrough in the hunt for broad-spectrum malaria therapy

Scientists at La Trobe University have discovered a new antibody-like molecule which could be used in therapy to prevent infection from multiple malaria parasite species. The research, recently published in Nature Communications, found that when the molecule WD34 binds with a protein produced by malaria parasites, it inhibits their ability to infect cells at different stages of the disease. Led by Professor Michael Foley, Professor Robin Anders and PhD candidate Dimuthu Angage at the La Trobe Institute for Molecular Science (LIMS), the research also showed that WD34 can protect against several different malaria parasite species. Professor Foley said the discovery…

  • Medical Health Aged Care
  • 06/09/2024
  • 10:16
Royal Australian College of GPs

NSW Government’s expanded role for pharmacy is reckless and unsafe for patients: RACGP

The New South Wales Government’s move to expand the scope of pharmacists to treat a range of conditions is politically driven and risks the health of people across the state, says the Royal Australian College of GPs. Health Minister Ryan Park made the announcement at a Pharmacy Guild conference last night that work was underway to expand pharmacists' scope to treat ear infections, wound management, nausea, gastro-oesophageal reflux disease, acne, and muscle and joint pain. RACGP NSW Chair Dr Rebekah Hoffman slammed the move as reckless and putting politics before patient safety. “This is politically driven policy, and it has…

  • CharitiesAidWelfare, Medical Health Aged Care
  • 06/09/2024
  • 05:00
Lloyds Auctioneers and Valuers

Bid for a Cause: Whisky Auction Supports Brain Cancer Fight

After Jack was diagnosed with Glioblastoma Multiforme (GBM), one of the most aggressive and deadly brain cancers, he was given just 12 months to…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.